



Medicines & Healthcare products Regulatory Agency

MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed "Disclosure Log request" to:

FOI_policy@mhra.gsi.gov.uk

As long as it is headed correctly it will not be treated as a new FOIA request. The identity of the original requester will be redacted.

Updated: 31 Oct 2017

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/198	Request for M&A Pharmachem inspection reports	16/06/2017	Disclosed in part
17/199	Summary of inspection report	12/06/2017	Disclosed in part
17/200	The number of clinical trials applications approved by MHRA by year for 2014, 2015 and 2016 for (a) first-in-man studies (b) all Phase 1 studies (c) Phase 1 studies with an adaptive design.	12/06/2017	Disclosed in full
17/201	FOI 17/069 - Lariam/Mefloquine Antimalarial	20/06/2017	Disclosed in full
17/202	Assessments on the impact of leaving European Medicines Agency	26/05/2017	Not held
17/203	Clinical trials involving children your Agency has authorised since 2007	21/06/2017	Disclosed in full
17/204	All Inspection reports for the life CRO	16/06/2017	Not held
17/206	Further information on number of adverse incident reports MHRA has received of infections relating to contact lenses	22/06/2017	Disclosed in full
17/207	Inspection report for TC BIOPHARM LIMITED	23/06/2017	Disclosed in part
17/210	Information on DeepMind	07/06/2017	Disclosed in full
17/211	Request for assessment report for positive opinion for a new indication for Triptorelin	14/07/2017	Disclosed in part
17/212	Since 2008 reported cases to hpv vaccine	03/07/2017	Disclosed in full
17/213	The number of ADRs under the Yellow Card Scheme per annum since 2010	22/06/2017	Disclosed in full
17/214	Records showing: the total number of UK spontaneous ADR reports received by the MHRA for all medicines and vaccines for the following years: 2016,2015 and 2014.	27/05/2017	Disclosed in part
17/215	FOI request for Gliclazide RMP	23/06/2017	Disclosed in part
17/216	List of imported to UK for EU batch release products	16/06/2017	Disclosed in full
17/218	Incident data for medical devices used for moving and handling	26/06/2017	Disclosed in part
17/219	Premarketing clinical trials for fluoxetine	27/06/2017	Disclosed in part
17/220	Data on snake venom MA's	19/06/2017	Disclosed in full
17/221	List of Active substance Manufactures	22/06/2017	Disclosed in part
17/222	Request for estimation of the amount of money required in exchange for obtaining information.	03/07/2017	Disclosed in part
17/223	Was DeepMind's testing of Streams in Royal Free between December 2015 and May 2016 completely in line with MHRA regulations? If not, why not?	07/07/2017	Disclosed in full
17/226	Copy of the Wockhardt report	03/07/2017	Disclosed in full
17/227	Human Papillomavirus (HPV) vaccine - [Redacted Section 35 Formulation of Government policy]	23/06/2017	Disclosed in full
17/228	Under freedom of information could I ask how many centres have reported these and how many per centre over the last 3 years?	27/06/2017	Disclosed in part
17/231	Dysport and Azzalure	29/06/2017	Disclosed in part
17/233	Marketing authorization Vm 04188/4024	13/06/2017	Not held
17/234	ADR for P-glycoprotein and CYP3A4 inhibitors	13/06/2017	Not held
17/238	Total number of UK suspected adverse drug reactions following any human papillomavirus (HPV) vaccine since 01/01/2008 (to present day).	11/07/2017	Disclosed in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/239	RMP for the active substance from Actavis (PL 30306/0573)	15/06/2017	Disclosed in part
17/241	UK Consensus Group on Malaria Prophylaxis	16/06/2017	Not held
17/243	Annual average spend, number of users, duration, contract dates and internal contact details on organisations mobile phones	10/07/2017	Disclosed in full
17/244	Follow up questions on FOI 17/184 on the number of abortion pills seized by year for the last 10 years	28/07/2017	Disclosed in full
17/247	Post ssri sexual dysfunction	18/07/2017	Disclosed in part
17/250	Follow up to Larium asking "Could you please provide copies of the application, with supporting documents, made by the licence holder asking for permission to vary the licence to increase drug dosing for up to 12 months, and a copy of the authority by the regulator to do so?"	20/07/2017	Disclosed in part
17/251	EPAR and RMP for Liothyronine – PL 12762/0176 and/or Liothyronine AmCo (Concordia) PL 10972/0033	21/06/2017	Disclosed in full
17/252	Tomudex UKPAR : PL 04515/0225	12/07/2017	Not held
17/253	Intellectual property (IP) held by MHRA, NIBSC and CPRD	20/07/2017	Disclosed in full
17/254	EPAR and RMP for Liothyronine Tablets – PL 20117-0270	04/07/2017	Disclosed in part
17/255	Educational Material for Bosentan	17/07/2017	Disclosed in part
17/256	Inspection Report	14/07/2017	Disclosed in part
17/257	Clinical and non-clinical overview of Pulmozyme	18/07/2017	Disclosed in part
17/258	List of the current GMP Contract Testing Labs	20/07/2017	Disclosed in full
17/259	Dosing regimen for Lariam	17/08/2017	Disclosed in part
17/260	Average prescription for Lariam (mefloquine Hydrochloride)	30/06/2017	Not held
17/261	What document's do you hold documenting adverse events to the Begrivac vaccine and I would like to request a copy of those document's please	21/07/2017	Disclosed in full
17/262	CPRD data	29/06/2017	Disclosed in full
17/263	Could you please provide in electronic format, including product name, MA holder, and MA number, a list of all active MAs in UK where the registered batch release site is based in the post-Brexit EU 27.	19/07/2017	Disclosed in full
17/264	Inspection report Kopran Ltd	24/07/2017	Disclosed in part
17/265	Adverse incident reports received by the MHRA for Stress Urinary Incontinence mesh tapes for the following dates. 2014 - 2017	21/07/2017	Disclosed in full
17/266	Payments to celebrities FOI	25/07/2017	Not held
17/268	Request for information under s.1 of the Freedom of Information Act 2000	07/07/2017	Not held
17/269	Yellow Cards for the HPV vaccination where the patient with the suspected adverse reaction was male from 1st November 2015 to 31st May 2017	27/07/2017	Disclosed in part
17/271	Can I please request the clinical AND non-clinical data for Sinemet Tablets, including the date of authorisation and the legal basis of the application	25/07/2017	Disclosed in part
17/272	Please provide redacted copies of the reports for the MHRA GMDP inspections conducted in June 2013 and November 2016 for: BARD PHARMACEUTICALS LIMITED	25/07/2017	Disclosed in part
17/273	Freedom of Information (FOI) request - QP Availability	28/07/2017	Disclosed in full
17/275	Information on Prozac/fluoxetine (PL 21880/0153-0156)	24/07/2017	Disclosed in full

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/276	Licence for Nitisinone in the UK	20/07/2017	Disclosed in full
17/278	Information on products containing (CBD)	02/08/2017	Disclosed in part
17/279	MA information on ZADITEN Tablets 1mg, PL 08381/0010	19/07/2017	Not held
17/280	CHM papers - (HPV) vaccines, including Yellow Card data	03/08/2017	Disclosed in part
17/281	Communication with any Government official regarding TPD/TRPR	03/08/2017	Disclosed in full
17/283	Summary Minutes for CHM meeting on 16th & 17th July 2015 - HPV	03/08/2017	Disclosed in full
17/284	Please send a copy of the current risk management plan for Frisium® 10mg Tablets (Clobazam) PL 04425/0214 SANOFI	25/07/2017	Not held
17/285	Could you please supply me with all relevant details of the trials that took place in order to justify the granting of a licence for levothyroxine sodium.	27/07/2017	Disclosed in part
17/286	I am looking for an old public assessment report of Glucophage and specifically the one related to the procedure: PL 11648/0054, MAH of which is merck serono	14/07/2017	Not held
17/287	I would like a list of the current and withdrawn Marketing Authorisations of medicinal products which contain the active substance Ketotifen	20/07/2017	Disclosed in part
17/289	Requesting you to share PAR for below mentioned finished products for our reference which is not available in agency's portal 1. Bisacodyl Suppositories, 2. Clotrimazole Pessaries and 3. Paracetamol Suppositories	11/07/2017	Disclosed in full
17/290	Can I receive a copy of the BARD response to enquiries about the Mesh implant	11/07/2017	Disclosed in full
17/291	I would like to request under the freedom of information act, how many reported adverse reactions were there reported of the routine 4 months vaccination in 2009? Dtap/hib/men c vaccine. How many mild reactions, severe and how many deaths were reported?	27/07/2017	Disclosed in full
17/292	RMP of the innovator PABAL	13/07/2017	Not held
17/293	Azzalure and Dysport	24/07/2017	Disclosed in full
17/294	I would specifically like to know if you have any data on metal ion toxicity in Birmingham hip patients to better inform my choice	28/07/2017	Not held
17/295	Information request on tretinoin import licences in 2016	31/08/2017	Disclosed in part
17/296	Bosentan Educational materials	07/08/2017	Disclosed in part
17/298	ADRs MEDI4736 - Sponsor: Astra Zeneca AB	25/07/2017	Disclosed in full
17/299	PAR - Glucophage 500mg modified release	25/07/2017	Not held
17/300	ADRs Gardasil and Gardasil 9 - COMBINE FOI 300 & 301	14/08/2017	Disclosed in full
17/301	Annual report for JCVI detailing vaccine-associated ADRs	14/08/2017	Disclosed in full
17/302	Information on Risk management plans	09/08/2017	Disclosed in part
17/303	deaths in persons aged 24 or over in clinical trials for Prozac	14/08/2017	Disclosed in part
17/305	Inspection report for Surepharm, Bretby, Burton-on-tent, DE15	10/08/2017	Disclosed in part
17/306	ADRs data and sources used for Stress Urinary Incontinence mesh tapes	21/08/2017	Disclosed in full
17/310	ADRs unlicensed Butterbur (Petasites hybridus) Herbal remedies	22/08/2016	Not held
17/307	Information about Reloxin & Azzalure	16/08/2017	Disclosed in part
17/311	Copies of RMP's for any Clobazam containing products	17/08/2017	Disclosed in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/313	IT & Information Security	21/08/2017	Disclosed in part
17/314	Copy of the latest report of the MHRA for Joint Committee on Vaccination and Immunisation: VACCINE-ASSOCIATED SUSPECTED ADVERSE REACTIONS REPORTED VIA THE YELLOW CARD SCHEME: Adverse reactions to Vaccines	14/08/2017	Disclosed in full
17/317	Information on ICT contract(s) for Server Hardware Maintenance Storage Area Network (SAN)	24/08/2017	Disclosed in full
17/318	List of data privacy observations made MHRA PV inspections 01 JUL 2015 – 01 JUL 2017	25/08/2017	Not held
17/319	Full current MHRA organogram including contact names, emails, therapeutic responsibilities, PLAT heads and assessors details.	02/08/2017	Disclosed in full
17/320	Keytruda licensing information	01/08/2017	Disclosed in part
17/321	PAR for Decapeptyl SR 3 mg, powder for suspension for injection - PL 34926/0002	09/08/2017	Disclosed in part
17/322	Inspection report	22/08/2016	Disclosed in part
17/323	Opeartion pangea information	29/08/2017	Disclosed in part
17/324	AIC report for orthopaedic, gynaecology, general and vascular devices from 2000 to date	29/08/2017	Disclosed in full
17/325	Information on Lasmiditan	24/08/2017	Disclosed in full
17/326	MHRA correspondence	26/09/2017	Disclosed in part
17/327	ADR HPV injection	29/08/2017	Disclosed in full
17/328	Data for Versatis medicated plaster licensing	24/08/2017	Disclosed in full
17/329	Yellow card data on various products	30/08/2017	Disclosed in full
17/332	HPV vaccine, Teenage 3-in-1 vaccine and MMR vaccine Drug Analysis Prints (DAP)	30/08/2017	Disclosed in full
17/333	Sources of MHRA funding	09/08/2017	Disclosed in full
17/334	Liothyronine info	22/09/2017	Disclosed in part
17/335	Copy of the paper provided by MHRA for the JCVI: 'Vaccine-associated suspect adverse reactions reported via the Yellow Card Scheme during 2015/16	09/08/2017	Disclosed in full
17/336	Inspection report	04/09/2017	Not held
17/337	Inspection report	04/09/2017	Disclosed in part
17/338	AIC details for CE products	29/08/2017	Disclosed in full
17/339	PAR for Decapeptyl SR 3 mg	31/08/2017	Not held
17/341	Clinical organ perforation	05/09/2017	Disclosed in full
17/353	List of inspectors	05/09/2017	Disclosed in full
17/354	Information about whooping cough vaccine	23/08/2017	Not held
17/355	ADR info	06/09/2017	Disclosed in part
17/356	Information on opiates	04/09/2017	Disclosed in part
17/359	ADRs & RMP Pregabalin oral solutions	11/09/2017	Disclosed in part
17/360	Inspection report	08/09/2017	Disclosed in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/361	17/105 reports relating to HPV vaccines & 17/118 toxicity of HPV vaccine	06/09/2017	Disclosed in full
17/362	Information about liothyronine changes	31/08/2017	Disclosed in full
17/363	ADR - 5-in-1, (single jab diphtheria, tetanus, whooping cough (pertussis), polio and Haemophilus influenzae type b (Hib), Pneumococcal (PCV) vaccine, Rotavirus vaccine, and Men B vaccine	24/08/2017	Disclosed in full
17/364	List of Airways suction devices in digital format via e-mail for an article on enquirers blog	04/09/2017	Disclosed in part
17/365	Kitazato's CE certification renewal for vitrification media VT801/VT802	24/08/2017	Disclosed in full
17/367	Updated list of CFS team	01/09/2017	Disclosed in full
17/369	Inspections and/or enforcement info on Star150/Star150.com and African Compass Trading	14/09/2017	Disclosed in part
17/370	Further Information about Dysport and copy of "Duty Doctor Botulism Protocol-January 2013	14/09/2017	Disclosed in full
17/371	How many deaths/incidents with slings in the last 20 years broken down types of incidents, root cause, detailed cause.	13/09/2017	Disclosed in part
17/372	Has anyone granted a licence for Nitisinone in the UK or Europe?	31/08/2017	Disclosed in full
17/373	Copy of RFIs submitted & clinical overview Liothyronine sodium 20mcg Tablets	18/09/2017	Disclosed in part
17/374	Request clinical & non-clinical data data Restandol Testocaps 40 MG capsule	19/09/2017	Disclosed in part
17/376	Risk Management Plans for products with the active substance Domperidone, Sodium Valproate,	20/09/2017	Disclosed in part
17/380	Electronic copies Clinical Trial Application (CTA) for the MGT009 study (EudraCT no: 2016-003967-21	22/09/2017	Disclosed in part
17/381	All GMP & GDP Post Inspection Letters not disclosed under previous FOI requests (FOI 16-415 & 16-416)	22/09/2017	Disclosed in part
17/382	Provide copy of the "Clinical Expert statement on the amendments, 6th PSUR Jan-Dec 1998" - PL 00031/0236-0024	25/09/2017	Disclosed in part
17/383	ADRs 5 in 1 vaccine, the pneumococcal, the MMR and the meningitis vaccines	26/09/2017	Disclosed in full
17/384	ADRs in last 5 years to mercury pharma Levothyroxine & Eltroxin.	23/10/2017	Disclosed in full
17/385	ADRs which caused patients sexual dysfunction by SSRIs	26/09/2017	Disclosed in full
17/386	Confirm names of companies which have imported Carmustine 100mg as an unlicensed product over 5 years.	27/09/2017	Disclosed in part
17/387	Information, stats and number of reported cases of permanent/ongoing alopecia from the drug Taxotere.	20/09/2017	Disclosed in full
17/388	Approved version of the educational materials for Levonorgestrel 1.5mg Tablets (OTC) in the UK.	25/09/2017	Disclosed in full
17/391	Can you advise if anyone granted a licence for Nitisinone in the UK or Europe?	12/09/2017	Disclosed in full
17/393	CPRD Gold data specification	11/09/2017	Disclosed in full
17/394	PAR Zestoretic	05/10/2017	Not held
17/395	Complete list of all medicines approved for prescription to patients on the NHS subsequent to EU Directive Clinical Trials – Regulation EU No 536/2014	27/09/2017	Not held
17/397	Last PV inspection reports of Pfizer, Janssen, Agouron & International Partnership for Microbicides.	09/10/2017	Disclosed in part
17/399	Published and unpublished pre marketing clinical trial data that was used by the Department of Health in giving sertraline a license for the treatment of depression	10/10/2017	Disclosed in part
17/401	RMP of Nicorette Quickmist 1mg/spray Mouthspray	27/09/2017	Disclosed in part
17/402	Recent GMP Inspection and Inspection report/findings for: Pharnasol Ltd	11/10/2017	Disclosed in part

<i>FOI no</i>	<i>Subject</i>	<i>Date reply sent</i>	<i>Result of request</i>
17/403	Whether any applications have been refused for reclassifying Levonorgestrel (either 2x750mcg or 1.5mg) to GSL?	06/10/2017	Disclosed in part
17/404	Licence for Nitisinone in the UK or Europe	09/10/2017	Disclosed in full
17/405	Evidence of use of use of hyaluronidase to enhance the absorption of sedative drugs including alpha-2 agonists and benzodiazepines, given intramuscularly to pigs	20/09/2017	Disclosed in full
17/406	PAR for Tekcis 2-50 GBq radionuclide generator (PL 11876/0022)	27/09/2017	Disclosed in part
17/407	Inspection report	09/10/2017	Disclosed in part
17/408	Safety information on Etoricoxib	09/10/2017	Disclosed in full
17/410	How many adverse incidents reports for surgical mesh devices in Wales	13/10/2017	Disclosed in full
17/411	Inspection report for Product Life CRO	12/10/2017	Disclosed in part
17/412	RMP Co-codamol 15/500mg tablets	02/10/2017	Disclosed in part
17/413	RMP Aspirin-dipyridamole	10/10/2017	Disclosed in part
17/414	RMP Dexamethasone 2mg Tablets	03/10/2017	Disclosed in part
17/415	CHM meeting information October 2015	16/10/2017	Disclosed in part
17/416	All PILs for Sertraline from 1990-2017	05/10/2017	Disclosed in full
17/418	Data on SAR received in the Agency	16/10/2017	Disclosed in full
17/419	Yellow card data used for medicines recall	17/10/2017	Disclosed in full
17/420	Inspection report	16/10/2017	Disclosed in part
17/421	Data on SAR received in the Agency	10/10/2017	Disclosed in full
17/422	System used for FOI	28/09/2017	Disclosed in part
17/423	All MHRA reports pertaining to the market authorisation of Lustral 50mg and 100mg Tablets (PL 00057/0308-9) provided to Pfizer Limited November in 1990	11/10/2017	Disclosed in part
17/424	Policy on information on PIL/working with NHS England	20/10/2017	Disclosed in full
17/425	AIC information on breast implants	13/10/2017	Disclosed in full
17/428	Drug print outs for a list of vaccines	23/10/2017	Disclosed in full
17/429	Falsified medicines information - regulatory	23/10/2017	Disclosed in full
17/432	PAR Clarithromycin	10/10/2017	Disclosed in full
17/433	Information regarding the QPPV acting for Cox Pharmaceutical Limited	02/10/2017	Disclosed in full
17/434	Information on details of emails refused for FOI 17/060	27/10/2017	Disclosed in full
17/447	How many licenses have been provided for steroid storage	24/10/2017	Not held